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Background—Nonadherence to antihypertensive treatment is a common problem in cardiovascular prevention and may
influence prognosis. We explored predictors of adherence to antihypertensive treatment and the association of adherence
with acute cardiovascular events.
Methods and Results—Using data obtained from 400 Italian primary care physicians providing information to the Health
Search/Thales Database, we selected 18 806 newly diagnosed hypertensive patients 35 years of age during the years
2000 to 2001. Subjects included were newly treated for hypertension and initially free of cardiovascular diseases. Patient
adherence was subdivided a priori into 3 categories—high (proportion of days covered, 80%), intermediate
(proportion of days covered, 40% to 79%), and low (proportion of days covered, 40%)—and compared with the
long-term occurrence of acute cardiovascular events through the use of multivariable models adjusted for demographic
factors, comorbidities, and concomitant drug use. At baseline (ie, 6 months after index diagnosis), 8.1%, 40.5%, and
51.4% of patients were classified as having high, intermediate, and low adherence levels, respectively. Multiple drug
treatment (odds ratio, 1.62; 95% CI, 1.43 to 1.83), dyslipidemia (odds ratio, 1.52; 95% CI, 1.24 to 1.87), diabetes
mellitus (odds ratio, 1.40; 95% CI, 1.15 to 1.71), obesity (odds ratio, 1.50; 95% CI, 1.26 to 1.78), and antihypertensive
combination therapy (odds ratio, 1.29; 95% CI, 1.15 to 1.45) were significantly (P0.001) associated with high
adherence to antihypertensive treatment. Compared with their low-adherence counterparts, only high adherers reported
a significantly decreased risk of acute cardiovascular events (hazard ratio, 0.62; 95% CI, 0.40 to 0.96; P0.032).
Conclusions—The long-term reduction of acute cardiovascular events associated with high adherence to antihypertensive
treatment underscores its importance in assessments of the beneficial effects of evidence-based therapies in the
population. An effort focused on early antihypertensive treatment initiation and adherence is likely to provide major
benefits. (Circulation. 2009;120:1598-1605.)
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High blood pressure (BP) is one of the most preventablecauses of cardiovascular disease morbidity and mortal-
ity.1 The use of antihypertensive drug therapy (AHT) has
been shown to reduce the risk of stroke and coronary heart
disease by an estimated 34% and 21%, respectively, in
long-term randomized controlled trials (RCTs).2,3 Generally,
AHT should be maintained indefinitely. However, findings in
clinical practice have raised concerns about the high extent of
undertreatment and nonadherence to AHT, which hampers
the effectiveness of these medications. In RCTs, antihyper-
tensive drug discontinuation rates range from 5% to 10% per
year, and rates up to 50% to 60% after 6 months have been
reported in actual practice.4,5
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Adherence to AHT has been associated with improved BP,
decreased hospitalizations rates, and lower medical care
costs.3,6 A recent cohort study7 has also confirmed that the
long-term survival advantages associated with improved ad-
herence to AHT after acute myocardial infarction (AMI)
appear to be class specific and correlated positively in a
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Hypertension
dose-response–type fashion. This evidence suggests that the
benefits associated with adherence to evidence-based thera-
pies are mediated by drug effects rather than the adoption of
healthier lifestyles that often accompanies adherent behaviors
(ie, healthy adherer effect).
To the best of our knowledge, less attention has been paid
to understanding how nonadherence to AHT might affect the
occurrence of cardiovascular events (CVEs) among patients
who had not experienced any major cardiovascular outcome.
The aim of the present study was to describe adherence to
AHT and its association with concurrent drug use, comor-
bidities, and cardiovascular risk factors. Furthermore, we
assessed the impact of adherence on the incidence of CVE
among newly diagnosed hypertensive patients.
Methods
Sources of Data
We obtained information from the Health Search/Thales Database,
an Italian general practice registry that comprises data given by
computer-based patient records of a selected group of primary care
physicians (PCPs) distributed across Italy. They voluntarily agreed
to collect patient information and to attend specified training courses
for data entry.
The Health Search/Thales Database contains patient demographic
details that are linked through the use of an encrypted patient code
with medical records (diagnoses, tests, and tests results), drug
prescription information (medication name, date of filled prescrip-
tion, and number of days’ supply), prevention records, hospital
admission, and date of death. To be considered for participation in
epidemiological studies, PCPs should meet “up-to-standard” quality
criteria pertaining to the levels of coding, prevalence of well-known
diseases, mortality rates, and years of recording.8
A number of comparative studies have been published confirming
the research validity of the Health Search/Thales Database in
conducting studies on the observed outcomes.9–11 When this study
was initiated, 400 PCPs homogeneously distributed across all Italian
areas, covering a patient population of 521 214, reached the up-to-
standard quality criteria.
Cohort Definition
We identified all subjects35 years of age who were diagnosed with
hypertension (International Classification of Diseases, 9th revision,
clinical modification [ICD-9-CM] codes 401 through 404.x and
437.2) during the years 2000 to 2001 and were newly treated with at
least one of the possible antihypertensive drugs (ie, diuretics,
-blockers, -blockers, angiotensin-converting enzyme inhibitors,
calcium channel blockers, angiotensin-2 receptor blockers) in the 90
days after index diagnosis. Patients were considered newly treated if
they had not taken any AHT 6 months before the index diagnosis.
Patients included in the study cohort were registered with one of the
participating PCPs for at least 1 year before entry into the study and
survived at least 1 year after index diagnosis.
We excluded any patient who had been diagnosed with coronary
heart disease (codes 410 through 414.x), cerebrovascular disorders
(codes 430 through 438.x), or congestive heart failure (code 428.x);
subjects who had been hospitalized for coronary artery bypass
surgery or coronary angioplasty, and those recovered in a cardiolog-
ical ward before index diagnosis. To avoid the tendency of PCPs to
diagnose and treat hypertension as an early manifestation of major
cardiovascular disease that had not yet been diagnostically detected
or confirmed (ie, survival bias), we excluded patients reporting
incident CVE in the 180 days after index diagnosis.7,12 We also
excluded subjects receiving nitrates because such medications are
prescribed among patients with coronary heart disease even in
absence of an appropriate diagnostic recording.10
Subjects were followed up from the date of the index diagnosis
until the first-ever CVE or the end of the study period (December 31,
2005). Individuals who transferred from his or her PCP or died
during follow-up were censored.
Assessment of Adherence
Adherence to AHT, defined as the extent to which patients followed
their antihypertensive medication schedules as prescribed by their
PCPs,13 was estimated by calculating the proportion of days on
which a patient had pills available during the follow-up (proportion
of days covered [PDC]). The follow-up period was separated into
180-day intervals, and within each interval, the PDC corresponded to
the total number of days’ supply of medication dispensed divided by
the length of the corresponding follow-up and multiplied by 100. The
number of days supplied by each prescription was calculated by
dividing the total amount of active drug in each prescription by the
recommended defined daily dose. Prescriptions filled before the
beginning of each interval could contribute if the days supplied
extended into the interval period. Prescriptions filled at any point
after the start of the interval contributed days from the date dispensed
forward.
Consistent with data in the literature,7,13 patients were classified
into the following adherence levels: high (PDC 80%), intermediate
(PDC, 40% to 79%), or low (PDC 40%).7 They were further
classified into single therapy if taking 1 antihypertensive drug class
or combination therapy if multiple-pill medications such as angio-
tensin-converting enzyme inhibitors and calcium channel blockers or
a fixed-dose combination therapy (ie, angiotensin-converting en-
zyme inhibitors plus diuretics) was prescribed for 50% of days
during each time interval.
Acute Cardiovascular Events
The onset of any acute CVE was ascertained through the physician’s
coded diagnosis during follow-up. A CVE was defined as a com-
posite end point of first-ever acute coronary syndromes such as AMI
(codes 410.x and 411.x) and angina pectoris (code 413.x) or
cerebrovascular events such as acute stroke (codes 430 through
432.x, 433.01, and 436.x) and transient ischemic attack (code 435.x).
The reliability of the coded diagnoses was assessed by manual
review of the “free text” electronic medical charts. Validation
procedures were performed by the use of encoded medical problems,
which primarily allowed us to confirm the occurrence of an acute
event (ie, “acute,” “sudden,” “heart attack,” “stroke,” “hemor-
rhage*,” “recovery,” “hospital*”) leading to angina/transient ische-
mic attack (ie, “ischemi*,” “occlusion,” “obstruction,” “stenosis,”
“transient”) or AMI/stroke (“infarct*,” “necrosis”).
Cardiovascular Risk and Comorbidity
To control for global cardiovascular risk, we identified most of the
documented variables potentially associated with coronary heart
disease and stroke.14 They included age, gender, familiar history of
cardiovascular disease, BP values (calculated as the average between
the last 2 separate measurements over the 12 months before the index
diagnosis), and obesity (body mass index 30 kg/m2 [last available
value for the 12 months before the index diagnosis] or ICD-9-CM
code 278.0). Coexisting illnesses were ascertained from physician
ever-recorded diagnosis and medication use. We used a previously
validated approach15 to identify diabetes mellitus on the basis of PCP
diagnosis (codes 250.x, excluding 250.x1 and 250.x3) and 1
antihyperglycemic medications. Dyslipidemia was based on PCP
diagnosis (code 272.x) and receipt of lipid-lowering therapy.16 We
also identified arrhythmias (code 427.x), peripheral vascular diseases
(code 443.9), cancer (codes 140 through 199.x, 200 through 208.x),
and chronic respiratory diseases (codes 490 through 496.x). Drug
information was used to assign prior and follow-up receipt of
relevant medications, including antihyperglycemic agents, anti-
thrombotics, cardiac glycosides, lipid-lowering agents, antiarrhyth-
mics, corticosteroids, thyroid therapy, nonsteroidal anti-
inflammatory drugs, and antidepressants, for each eligible person.
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Statistical Analysis
To analyze differences in baseline characteristics across adherence
levels, we tested for linear trends using a 2 test (categorical
variables) or linear regression models (continuous variables) when
appropriate. Multivariable logistic regression models, adjusting for
all baseline factors, were constructed to examine predictors of high
adherence to AHT.
The relationship between adherence and incident CVE was exam-
ined by constructing multivariable Cox proportional-hazards models.
To adjust for potential confounders, we included age, gender,
baseline concomitant medical treatment, comorbidity, obesity, fam-
ily history of cardiovascular diseases, BP values, and hospitalization
for the 12 months before the index diagnosis (Table 1). In addition,
we considered cardiovascular risk factors and concurrent drug use as
time-dependent covariates in the model to adjust for global cardio-
vascular risk during follow-up (model 1). Adherence to AHT was
assessed at 2 different time windows: at baseline and during
follow-up.7,17,18 At baseline, AHT was determined during the first 6
months after the index diagnosis and evaluated on the basis of an
intention-to-treat approach. During follow-up, AHT was treated as a
Table 1. Characteristics of Newly Diagnosed Hypertensive Patients According to Baseline
Adherence to AHT
Adherence Levels*
Low Intermediate High P
Patients, n (%) 9666 (51.4) 7624 (40.5) 1516 (8.1)
Age, mean (SD), y 62.0 (12.4) 61.9 (11.9) 61.3 (11.6) 0.089
Women, n (%) 5787 (59.9) 4384 (57.5) 800 (52.8) 0.001
Concurrent drug use, n (%)†
Antihyperglycemic drugs, n (%) 741 (7.7) 794 (10.4) 200 (13.2) 0.001
Antithrombotics 1047 (10.8) 1136 (14.9) 267 (17.6) 0.001
Lipid-modifying agents 763 (7.9) 815 (10.7) 177 (11.7) 0.001
Antiarrhythmics 148 (1.5) 110 (1.4) 19 (1.3) 0.678
Corticosteroids 484 (5.0) 365 (4.8) 100 (6.6) 0.013
Thyroid therapy 406 (4.2) 325 (4.3) 73 (4.8) 0.544
NSAIDs 2757 (28.5) 2347 (30.8) 491 (32.4) 0.001
Antidepressant drugs 694 (7.2) 579 (7.6) 127 (8.4) 0.207
Concurrent medications, mean, n (SD)† 3.3 (2.6) 3.6 (2.8) 4.1 (2.9) 0.001
Comorbidity at index diagnosis, n (%)
Diabetes mellitus 915 (9.5) 890 (11.7) 208 (13.7) 0.001
Arrhythmias 295 (3.1) 332 (4.4) 66 (4.4) 0.001
Peripheral vascular diseases 300 (3.1) 280 (3.7) 73 (4.8) 0.002
Dyslipidemia 1048 (10.8) 979 (12.8) 221 (14.6) 0.001
Cancer 657 (6.8) 541 (7.1) 115 (7.6) 0.469
Respiratory illness 716 (7.4) 544 (7.1) 129 (8.5) 0.174
Obesity‡ 806 (8.3) 786 (10.3) 193 (12.7) 0.001
Family history of cardiovascular diseases 448 (4.6) 432 (5.8) 96 (6.3) 0.001
BP, mean (SD), mm Hg
Systolic 145.2 (17.8) 143.9 (17.1) 144.2 (17.5) 0.001
Diastolic 86.3 (9.9) 85.2 (9.5) 85.5 (9.4) 0.001
BP categories, n (%)§ 0.001
High normal 2293 (39.6) 2293 (42.7) 478 (42.6)
Mild 1849 (31.9) 1858 (34.6) 376 (33.3)
Moderate 1182 (20.4) 854 (15.9) 178 (15.8)
Severe 464 (8.0) 357 (6.7) 89 (7.9)
Patients with hospital recovery, n (%) 455 (4.7) 387 (5.1) 92 (6.1) 0.065
Antihypertensive drug use with 1-pill regimen
or multiple-pill combinations, n (%)
3061 (31.7) 2831 (37.1) 560 (36.9) 0.001
NSAIDs indicates nonsteroidal anti-inflammatory drugs.
*Adherence was defined as the PDC: high (PDC 80%), intermediate (PDC, 40% to 79%), or low (PDC 40%).
†Six months before the index diagnosis.
‡ICD-9-CM code 278.0 or body mass index 30 kg/m2.
§High normal, 130 to 139/85 to 99 mm Hg; mild hypertension, 140 to 159/90 to 99 mm Hg; moderate
hypertension, 160 to 179/100 to 109 mm Hg; severe hypertension, 180/110 mm Hg.3 Of 18 806 patients, 6535
(34.7%) did not recorded BP values at baseline.
Twelve months before the index diagnosis.
1600 Circulation October 20, 2009
time-dependent covariate in which each patient could contribute to
any adherence level within any 180-day interval.
As an observational study of clinical practice, concerns exist about
treatment selection bias. Adjusted estimates were therefore weighted
by the inverse estimated propensity scores in an additional Cox
proportional-hazards regression model of adherence effect (model
2).19,20 We developed 2 propensity score models to weight for
adherence selection: high versus low adherence and intermediate
versus low adherence.
Multivariable selection of risk factors was done by a stepwise
procedure after adjustment for age and gender. The best model
chosen by the stepwise procedure was confirmed by testing a range
of related models with the Akaike information criterion. Because of
the hierarchical structure of the variables, all statistical models
accounted for the clustering of registered patients within each
regional health authority.
Several sensitivity analyses were performed to ensure the consis-
tency of our primary analysis in the presence of potential biases.
Statistical significance was defined as a 2-tailed value of P0.05.
Estimates of treatment effects, 95% confidence intervals (CIs), and
probability values were generated with STATA software, version
10.1 (STATA Cor, College Station, Tex).
Results
After applying the inclusion and exclusion criteria, from
25 763 hypertensive patients newly diagnosed by PCPs dur-
ing 2000 to 2001, we selected 18 806 patients (73.0%) with a
mean age at entry of 62 years, 41.6% of whom were male,
and 27.5% of whom had at least 1 cardiovascular risk factor.
Determinants of Adherence
At baseline, 9666 (51.4%), 7624 (40.5%), and 1516 (8.1%)
patients were classified as having low, intermediate, and high
adherence, respectively. At the end of the follow-up, 1196
low and 1637 intermediate adherers switched to high adher-
ence. Of 1516 baseline high adherers, 43.5% maintained the
same category, whereas 31.0% and 25.5% switched to inter-
mediate and low adherence, respectively. Overall, 18.8% of
patients ended their follow-up with high adherence levels,
whereas the proportion of intermediate and low adherers was
32.3% and 48.9%, respectively (the Figure).
Table 1 illustrates baseline characteristics of hypertensive
patient according to 6 months of adherence to AHT. After
adjustment for relevant baseline factors (Table 2), older patients
(odds ratio [OR], 0.76; 95% CI, 0.68 to 0.86) and women (OR,
0.72; 95% CI, 0.65 to 0.86) were less likely to exhibit high
adherence. The risk of being a high adherer increased in the
presence of concurrent treatment with 5 medications (OR,
1.62; 95% CI, 1.43 to 1.83), antithrombotics (OR, 1.54; 95% CI,
1.31 to 1.80), and combination AHT (OR, 1.29; 95% CI, 1.15 to
1.45). Overall, most of the documented cardiovascular risk
factors (ie, diabetes mellitus, dyslipidemia, and obesity) had
significant (P0.001) associations with high adherence to AHT.
Impact of Adherence on Cardiovascular Events
During the follow-up (meanSD, 4.61.2 years per patient),
a total of 1018 patients (12.1 per 1000 person-years) were
censored because they transferred from their PCPs, and 541
patients (6.4 per 1000 person-years) died. The crude incidence
rates of acute CVEs were 7.4, 8.4, and 7.5 per 1000 person-years
for low, intermediate, and high adherers, respectively.
Table 3 illustrates that the adjusted relationship between
adherence and CVE (ie, model 1) followed a dose-response
gradient, although not statistically significant among interme-
diate adherers. Although the direction of the association was
similar, additional weighting for inverse propensity scores
estimates (ie, model 2) reduced the magnitude of association
between high adherence and the risk of acute CVE (hazard
ratio [HR], 0.62; 95% CI, 0.40 to 0.96), whereas the HR
among those with intermediate adherence remained similar
(HR, 0.86; 95% CI, 0.71 to 1.03). After weighting by the
inverse estimated propensity scores for high adherence selec-
tion, significant associations were reported for the following
covariates: antithrombotic use (HR, 0.50; 95% CI, 0.37 to
0.67), diabetes mellitus (HR, 2.38; 95% CI, 1.56 to 3.63), and
dyslipidemia (HR, 1.39; 95% CI, 1.11 to 1.73). No significant
association was reported for combination AHT.
Sensitivity Analysis
To ensure that our method did not introduce a survival bias,
we re-estimated the association between adherence to AHT
and CVEs among subjects without any major cardiovascular
outcomes for at least 90 and 365 days after the index
diagnosis. We also stratified the patient population according
Figure. Relative frequencies (percent) of
patient adherence to AHT at baseline (ie,
6 months after index diagnosis) and dur-
ing follow-up.
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to the presence of at least 2 cardiovascular risk factors to
ensure that any relationship between adherence and CVE also
applied to various risk groups. Although the observed asso-
ciations did not always achieve statistical significance be-
cause of sample size, subgroup analyses yielded trends
consistently shown in the primary analysis.
Discussion
The main finding of the present study is that high adherence
to AHT is associated with a 38% decreased risk of CVEs
compared with lower adherence. This result is similar in
magnitude to results presented in recent meta-analyses of
placebo-controlled trials, which reported a nearly 30% rela-
tive risk reduction of major CVEs achieved with different
antihypertensive drugs.2,21 The methods we applied to assess
the relationship between baseline adherence to AHT and
incident CVEs adapt 1 principle of the design of RCTs (ie,
intention-to-treat analysis).22 Studies from the United King-
dom,5 Canada,23 and the Netherlands24 have in fact demon-
strated that discontinuation rates are likely to be higher during
the first year of follow-up but are more likely to remain rather
stable thereafter for the long term.
The benefits of BP lowering may partially explain the
decreased risk of CVEs among high adherers. During follow-
up, we observed similar reductions of BP levels across the
adherence groups (see the online-only Data Supplement), in
accordance with an RCT documenting substantial benefit of
various antihypertensive drugs even when BP reductions are
small.25 Additional explanation is provided by several recent
studies26,27 that have suggested that early and rapid achieve-
ment of BP control with various antihypertensive drugs was
associated with significant benefits for subsequent CVEs.
Indeed, in hypertension, BP variability increases with in-
creasing BP levels, and there is evidence that its magnitude
correlates closely with target-organ damage and with the
incidence of CVE independently of absolute BP levels.28
Therefore, any antihypertensive drug capable of providing
smooth 24-hour BP control might confer additional target-
organ protection.29
Consistent with previous research,30 patients at higher risk
for adverse health outcomes, expressed as being treated with
5 medications,31 and those with higher baseline cardiovas-
cular risk showed stronger associations with high adherence
to AHT. Patients with severe clinical conditions are in fact
Table 2. Crude and Multivariable Analyses of the Association of Patient Baseline
Characteristics With Corresponding 6-Month High Adherence Level
OR (95% CI)
Crude* Adjusted†
High vs Low Adherence P High vs Low Adherence P
Age, y
65 · · · · · · 1.00
65 · · · · · · 0.76 (0.68–0.86) 0.001
Gender
Male · · · · · · 1.00
Female · · · · · · 0.72 (0.65–0.81) 0.001
Concurrent drug use‡
Antithrombotics 1.85 (1.59–2.16) 0.001 1.54 (1.31–1.80) 0.001
Concurrent medications
5 1.00 1.00
5 1.79 (1.59–2.02) 0.001 1.62 (1.43–1.83) 0.001
Comorbidity at index diagnosis§
Diabetes mellitus 1.65 (1.36–1.99) 0.001 1.40 (1.15–1.71) 0.001
Arrhythmias 1.56 (1.18–2.06) 0.002 1.37 (1.03–1.82) 0.029
Peripheral vascular diseases 1.60 (1.22–2.09) 0.001 1.32 (1.00–1.75) 0.046
Dyslipidemia 1.68 (1.37–2.05) 0.001 1.52 (1.24–1.87) 0.001
Obesity§ 1.61 (1.35–1.91) 0.001 1.50 (1.26–1.78) 0.001
Family history of cardiovascular diseases
No 1.00 1.00
Yes 1.41 (1.12–1.78) 0.003 1.40 (1.10–1.77) 0.005
Antihypertensive drug use
Monotherapy 1.00 1.00
Fixed-dose or multiple-pill combinations 1.29 (1.15–1.45) 0.001 1.29 (1.15–1.45) 0.001
*Age- and gender-adjusted.
†Adjusted for all variables included in the table and clustering by regional health authority.
‡Nonusers as reference.
§Absence of disease as reference.
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more aware of being at higher risk and therefore are more
willing to follow a therapeutic regimen. The small proportion
of baseline high-risk patients might therefore explain the
considerable suboptimal adherence to AHT encountered in
our study. Conversely, the improved adherence observed
during follow-up might be due to an increased cardiovascular
risk among the study sample. This hypothesis has been
confirmed in a recent study from the Netherlands32 that
revealed that the hospitalization for cardiovascular disease
(OR, 2.20; 95% CI, 1.84 to 2.63) and, to a lesser extent, the
prescribing of cardiovascular comedications (OR, 1.25; 95%
CI, 1.11 to 1.40) were each independently associated with
initiation of antihypertensive treatment after temporary dis-
continuation. However, several trials of AHT33,34 have dem-
onstrated that, despite intense BP lowering, the incidence of
CVEs remains much higher in high-risk hypertensive patients
than in hypertensive patients with initial lower risk. This
evidence suggests that some of the major cardiovascular risk
changes may be difficult to reverse and that restricting AHT
to high-risk patients may be a strategy that is far from
optimal.
The use of combination AHT has not reduced the incidence
of CVEs per se. This finding might be explained by the low
proportion of cardiovascular risk factors observed in our
sample. In fact, combination therapy has been found to be
more effective in diabetic, renal, and high-risk patients,35
whereas no conclusive evidence has been reported among
hypertensive patients at lower risk. However, we observed
improved adherence (30%) associated with combination
therapy compared with monotherapy. This result may support
a recent statement from the European Society of Hyperten-
sion and European Society of Cardiology guidelines,3 which
argued that the use of low-dose combinations favors compli-
ance because of the smaller side effects compared with
full-dose monotherapy and that BP targets may be reached
earlier than with monotherapy.
Previous researches have assessed the relationship between
survival and adherence to antihypertensive, lipid-lowering,
and antihyperglycemic drugs among patients discharged from
hospitals with coronary heart disease,7,36 congestive heart
failure,17 or diabetes mellitus.37 To the best of our knowledge,
this is one of the first studies to investigate the effect of
adherence to AHT on the occurrence of first-ever major CVE.
Another recent study38 explored the effect of early discontin-
uation of AHT on the risk of first-ever AMI and stroke.
Nonpersistent antihypertensive use was associated with a
15% and 28% increased risk of AMI and stroke, respectively.
However, although discontinuation to AHT is common, 50%
of patients are likely to reinitiate treatment within 1 year.5,17
This certainly demonstrates that compliance with AHT is a
dynamic factor that needs to be evaluated far beyond the
simple treatment withdrawal.
Limitations
Our study has several noteworthy limitations. First, we
confirmed the recorded diagnosis against medical charts, thus
decreasing the likelihood of including false positives. How-
ever, the completeness of the ICD-9-CM coding might be
questioned. Several studies have in fact estimated a sensitiv-
ity ranging from 60% to 80% for AMI diagnosis39 and the
likelihood of ascertainment bias for stroke diagnosis because
of the high case fatality rate.40 The potential misclassification,
however, is unlikely to be differential among the adherence
groups.
Second, our inability to track the time-varying global
cardiovascular risk for each patient might have limited the
comprehensiveness of risk adjustment. Nonetheless, our anal-
yses have been adjusted for many factors, including most of
the documented variables generally used to validate cardio-
vascular prediction scores such as BP, familiar history of
cardiovascular disease, diabetes mellitus, dyslipidemia, and
obesity.41 Finally, because the allocation of patients into
different adherence groups was not randomized, it might have
produced a resulting imbalance in the underlying cardiovas-
cular risk profile, and comparison among treatment groups
can generate biased results.42 However, we excluded from
analysis patients without any antihypertensive treatment, thus
removing 1 source of selection bias. A propensity score
method19,20 was also used to control for the baseline differ-
ences observed across the adherence groups. Sensitivity
analyses that stratified patient population according to vari-
ous cardiovascular risk groups confirmed the robustness of
our findings.
Conclusions
The real-world results from the present study indicate that
high adherence to antihypertensive medication is associated
with a relevant decrease in CVEs in the context of the primary
prevention of cardiovascular diseases. These findings empha-
size the need to optimize earlier and appropriate treatment
strategies to maximize the beneficial effects of evidence-
based therapies even among lower-risk hypertensive patients.
Therefore, a systematic effort to improve the adherence to
AHT is likely to provide major long-term benefits.
Table 3. Multivariable Analysis of the Association of Patient
Characteristics With First-Ever Acute Cardiovascular Event
Estimated by Cox Proportional-Hazards Models
Adherence Within 6 mo After Diagnosis HR* (95% CI) P
Model 1†
Low (PDC 40%) 1.00 0.001§
Intermediate (PDC, 40% to 79%) 0.87 (0.73–1.03) 0.117
High (PDC 80%) 0.50 (0.35–0.69) 0.001
Model 2†
Low (PDC 40%) 1.00 0.001§
Intermediate (PDC, 40% to 79%) 0.86 (0.71–1.03) 0.109
High (PDC 80%) 0.62 (0.40–0.96) 0.032
A total of 659 CVEs were considered in the models.
*All models were adjusted for clustering by regional health authority.
†Model 1: adjusted for age, gender, use of antithrombotics, 5 concurrent
medications, presence of diabetes mellitus, dyslipidemia, and prior hospitalization.
Time-dependent covariates included adherence to AHT, use of combination AHT,
antithrombotics, 5 concurrent medications, presence of peripheral vascular
diseases, diabetes mellitus, and dyslipidemia.
‡Model 2: model 1 additionally weighted by the inverse estimated propensity
scores.
§P values for the overall comparison between models with and without
adherence to AHT using the log-likelihood ratio test.
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CLINICAL PERSPECTIVE
It is important for clinicians to pay greater attention to early treatment initiation and adherence to antihypertensive
medications because adherence is a key factor determining the success of preventive measures for cardiovascular risk
reduction. Restricting appropriate treatment to only high-risk patients may be far from optimal because some of the major
cardiovascular risk factors might be difficult to reverse. Educational strategies and interventions involving both health
professionals and patients, which should focus on simplification of dosing regimens and patient trust in their physicians,
might improve patient motivation to take prescribed medication.
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